Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc (NYSE: EBS) is a leader in developing medical countermeasures for public health threats, with a focus on biodefense and emergency response solutions. This page provides investors and stakeholders with centralized access to official press releases, regulatory updates, and strategic developments from the life sciences innovator.
Discover timely updates on key initiatives including NARCAN distribution, government contract awards, and advancements in vaccine manufacturing. Our curated news collection covers earnings reports, partnership announcements, and progress on treatments addressing biological threats like anthrax and smallpox.
Stay informed about Emergent's role in global health security through updates on FDA submissions, manufacturing facility expansions, and collaborations with agencies like BARDA. Content is organized chronologically for easy tracking of operational milestones and financial performance.
Bookmark this page for direct access to verified corporate communications and analysis of how EBS navigates complex regulatory environments while maintaining its position as a critical partner in national preparedness programs.
Emergent BioSolutions (EBS) reported Q1 2021 financial results with total revenues of $343.0 million, an 78% increase from Q1 2020. The net income was $69.7 million, compared to a loss of $12.5 million in Q1 2020. Adjusted EBITDA rose to $123.5 million, up from $15.3 million. Product sales decreased by 7% to $137.9 million, primarily due to lower sales of certain products. Revenue from contract development and manufacturing services surged to $183.8 million, attributed to partnerships addressing COVID-19. The company revised its 2021 revenue forecast to $1.7 - $1.9 billion.
The FDA has completed its inspection of Emergent BioSolutions' Baltimore-Bayview facility, providing specific feedback to enhance operations. Emergent is committed to collaborating with the FDA and Johnson & Johnson to address identified issues promptly. While acknowledging the shortcomings, the company expresses confidence in rectifying them quickly, emphasizing its workforce's dedication to producing high-quality COVID-19 vaccines. The press release highlights the importance of maintaining strong relationships with manufacturing partners and outlines the specific steps necessary for operational improvements.
Emergent BioSolutions (NYSE: EBS) will hold a conference call on April 29, 2021, at 5:00 PM ET to discuss its Q1 2021 financial results and revenue guidance for Q2 and the full year 2021. The call will cover recent business developments and provide insights into the company's financial outlook. Investors can join via telephone or webcast. For more details and to access the replay, visit the Emergent website.
Emergent BioSolutions (EBS) has received a $23 million increase in its task order from HHS for additional biologics manufacturing equipment. This funding is aimed at supporting Johnson & Johnson’s COVID-19 vaccine production, specifically enhancing manufacturing capabilities at the Baltimore Bayview facility.
The company reaffirms its 2021 financial guidance and reports no changes to its manufacturing agreements related to COVID-19 vaccines. Emergent is committed to strengthening the supply chain for Johnson & Johnson’s vaccine, with an annual production capacity exceeding one billion doses.
Emergent BioSolutions (NYSE:EBS) announced an update on its investigational COVID-HIG therapy following disappointing results from the Phase 3 ITAC trial. The trial revealed that the addition of COVID-HIG to standard care did not confer clinical benefits for hospitalized COVID-19 patients with symptoms for less than 12 days. Despite this setback, Emergent emphasized the importance of earlier interventions and plans to explore COVID-HIG further in ongoing trials. The government-backed initiative has gathered data from nearly 600 patients across 63 sites globally, with no serious safety concerns identified.
Emergent BioSolutions (NYSE: EBS) will participate in several upcoming investor conferences, showcasing its commitment to growth and communication with stakeholders. Key dates include:
- Jefferies Inaugural Global Plasma Summit on March 11, 2021, at 12:50 PM EST.
- KeyBanc Life Sciences & MedTech Investor Forum on March 24, 2021, at 1:15 PM EST.
- Chardan 4th Annual Manufacturing Summit on April 26-27, 2021, with updated details on the Emergent website.
- Truist 7th Annual Life Sciences Summit on May 4-5, 2021, with presentation details to be announced.
These events will likely discuss recent developments and financial guidance.
Emergent BioSolutions reported exceptional financial results for Q4 and full year 2020, with total revenues of $583.0 million for Q4, up 62% year-on-year, and $1,555.4 million for the full year, a 41% increase. Net income for Q4 surged to $185.4 million, improving net income per diluted share to $3.44. The company reaffirmed its 2021 revenue forecast of $1,950 - $2,050 million, citing robust CDMO services and product sales growth, particularly in response to COVID-19. Notable initiatives included expanding manufacturing capacity and signing new agreements for drug product manufacturing.
Emergent BioSolutions (NYSE: EBS) will host a conference call on February 18, 2021 at 5:00 PM ET to discuss Q4 2020 financial results, recent business developments, and 2021 revenue guidance. Investors can access the call via phone at (855) 766-6521 (toll-free) or via webcast at this link. A replay will be available on the Emergent website post-call. The company aims to enhance public health and protect lives through its products and services.
Emergent BioSolutions and Humanigen have entered into a contract development and manufacturing (CDMO) agreement to accelerate production of lenzilumab, an antibody aimed at treating COVID-19 related cytokine storms. The deal leverages manufacturing capacity reserved by the U.S. government through the Department of Defense and aims for an emergency use authorization (EUA) in Q1 2021. Emergent's advanced facilities in Baltimore will support increased production, forming a key part of Humanigen's growth strategy.
Emergent BioSolutions (NYSE: EBS) announced participation in key investor conferences for Q1 2021. These include:
- 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021, with a presentation on January 11 at 8:20 am EST.
- J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference on March 1-3, 2021, with details to be updated on their website.
- Cowen 41st Annual Health Care Conference from March 1-4, 2021, also pending updates.
Webcasts will cover recent developments and financial results.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
